Related Experiment Video
Updated: Feb 16, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
Published on: August 24, 2019
Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through
Yue Zhao1, Qinglong Guo1, Kai Zhao1
1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, China.
Abstract:
Emerging evidence suggests that NLRP3 inflammasome provides a link between colitis-associated colorectal cancer and inflammatory bowel diseases. Autophagy is induced in macrophages by AMPK activation and regulates NLRP3 inflammasome to maintain intracellular homeostasis. Here we report that a small-molecule AMPK activator (GL-V9) exerts potent anti-inflammatory effects on macrophages invitro and in vivo, which trigger autophagy to degraded NLRP3 inflammasome. Treatment with GL-V9 protected against colitis and tumorigenesis in colitis-associated colorectal cancer. This suggests that GL-V9 may be an interesting candidate for clinical evaluation in the treatment of colitis-associated colorectal cancer.
Insights
A novel AMPK activator, GL-V9, triggers autophagy to degrade NLRP3 inflammasome, reducing inflammation and protecting against colitis-associated colorectal cancer.
Area of Science:
- Immunology
- Molecular Biology
- Gastroenterology
Background:
- The NLRP3 inflammasome links inflammatory bowel diseases and colitis-associated colorectal cancer.
- Autophagy, induced by AMPK activation in macrophages, regulates the NLRP3 inflammasome for cellular homeostasis.
Purpose of the Study:
- To investigate the anti-inflammatory effects of a small-molecule AMPK activator, GL-V9.
- To determine if GL-V9 modulates the NLRP3 inflammasome pathway via autophagy.
Main Methods:
- In vitro and in vivo studies on macrophages treated with GL-V9.
- Assessment of autophagy induction and NLRP3 inflammasome degradation.
- Evaluation of GL-V9 efficacy in colitis and colitis-associated colorectal cancer models.
Main Results:
- GL-V9 demonstrated potent anti-inflammatory effects in macrophages.
- GL-V9 treatment induced autophagy, leading to the degradation of NLRP3 inflammasome.
- GL-V9 significantly protected against colitis and tumorigenesis in preclinical models.
Conclusions:
- GL-V9 effectively suppresses inflammation by activating autophagy and degrading NLRP3 inflammasome.
- GL-V9 shows therapeutic potential for colitis-associated colorectal cancer.
- Further clinical evaluation of GL-V9 for colitis-associated colorectal cancer is warranted.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Limiting Reactant
The Number e as a Limit
Types of Limits I
Limit Laws I
Protection of Alcohols
Protection
It defines a protecting group as the masking agent to make the more reactive species inert to a given set of conditions. This concept is depicted via the illustration of liquid flow through different outlets in an assembly of pipes. The analogy helps to understand the role...

